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Further observations on mechanisms of bone destruction by
squamous carcinomas of the head and neck: The role of host
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'Department ofPathology and 2Head and Neck Unit, Institute ofCancer Research and Royal Marsden
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Summary Mechanisms of bone invasion by squamous carcinomas of the head and neck have, been
investigated using fresh tumours and established tumour cell lines in an in vitro bone resorption assay with
45Ca-labelled mouse calvaria. Fresh tumours regularly resorb bone in vitro. Activity is consistently reduced by
indomethacin. The tumours release E2 prostaglandins (PGE2) in amounts sufficient to account for -50% of
the bone resorption observed. Small amounts of non-prostaglandin (indomethacin-resistant) osteolytic factors
are also produced. Control non-neoplastic tissues show a variable capacity to resorb bone in vitro; PGE2
levels in these tissues may be related to their content of inflammatory cells. Tumour cell lines also resorb bone
in vitro but, for most lines, activity is not significantly blocked by indomethacin and PGE2 levels are generally
insufficient to account for the osteolysis observed. Non-prostaglandin bone resorbing factors thus
predominate.
It is concluded that most squamous cancers of the head and neck are osteolytic in vitro and release a
mixture of prostaglandin and non-prostaglandin factors which stimulate osteoclastic bone resorption. These
factors are derived from both neoplastic and stromal elements, and are "tumour-associated" rather than
"tumour-specific". In vitro bone resorption and prostaglandin release does not correlate with pathological
features of the tumour or with post-operative survival.
Osteoclasts accumulate at sites of bone invasion by
squamous carcinomas of the head and neck, and
appear to play an important role in the destructive
process (Carter, 1982). Prostaglandins are known
stimulants of osteoclastic activity, and raised levels
of extractable prostaglandin-like material were
demonstrated by bioassay in a series of squamous
cancers from the head and neck region (Bennett et
al., 1980). Subsequent work showed that fresh
tumour tissues and tumour cell lines were osteolytic
in vitro and that bone resorption could be partly
blocked by indomethacin (Tsao et al., 1981). These
studies have been extended and information is now
presented on the identification and quantitation of
the prostaglandins involved and the contribution
made by host tissues as a source of osteolytic
factors. Observations on bone resorption by
xenografts of squamous carcinomas have been
reported separately (Tsao et al., 1983).
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Materials and methods
Bone resorption assay
The methods used were based on the procedure
devised by Reynolds (1968) and have been fully
described by us (Tsao et al., 1981). In brief,
calvaria were dissected from 5 to 7 day old BALB/c
mice previously injected with 45CaCl2, and cultured
on metal grids in modified Bigger's medium,
supplemented with heat-inactivated rabbit serum
and antibiotics, at 37°C in 5% CO2 in air. Paired
half-calvaria were used, one half of each serving as
a control. After a preliminary incubation period of
24h to equilibrate calcium exchange between bone
and culture medium, the calvaria were cultured for
3 days either with fresh tissue fragnents or with
various test and control media-see below. Release
of 45Ca was estimated by a liquid scintillation
system. The percentage of isotope released from
each bone was calculated and osteolysis was
expressed in a standard manner as the ratio of the
% of 45Ca release from test and control cultures.
The values of each bone resorption ratio were
recorded as the mean +s.e. of 4 pairs of bone
cultures.
In vitro osteolysis byfresh tissues
Twenty-nine squamous carcinomas were obtained
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from patients admitted to the Royal Marsden
Hospital for major surgery. The tumours were from
the following primary sites: tongue 6, hypopharynx
6, larynx 4, floor of mouth 3, oropharynx 3,
maxillary antrum 1 and nasal septum 1 together
with nodal metastases from primary carcinomas of
the tongue 3, larynx 1 and nasal septum 1.
Control (non-neoplastic) tissues were taken from
macroscopically uninvolved regions near the
resection lines of the same surgical specimen.
Observations were also made on normal breast skin
from patients admitted to Queen Mary's Hospital,
Roehampton and the Royal Marsden Hospital for
reduction mammaplasties.
Two methods were used to study in vitro
osteolysis. The fresh tissues were either directly co-
cultured with radiolabelled bone, or incubated
alone with culture medium and the conditioned
medium then assayed for osteolytic activity.
1) Co-culture experiments Tumour fragments
(_ 1 mm3) were weighed, washed with culture
medium and incubated with the 45Ca-labelled
calvaria for 3 days. Three-A pieces of tumour tissue
(net weight 9.5-28.2mg, mean 15.8) were either
placed round the bone or cultured on a separate
grid. The distance between the bone and the tissues
in both instances was 3mm. Five ml of culture
medium was used in each tumour-bone culture.
Full details of culture conditions were given
previously (Tsao et al., 1981) The release of 45Ca in
test and control bone cultures was estimated and
bone resorption ratios calculated. Control cultures
consisted of bone incubated without tumour.
Control (non-neoplastic) tissues were treated in the
same way.
2) Conditioned-medium experiments Fresh tissues
were incubated alone on metal grids for 3 days
( -20mg/5ml culture medium). Cell-free
supernatants were prepared after incubation by
Millipore filtration (0.45pm). Culture medium
incubated alone under the same conditions served
as a control. Media were stored at -40°C if not
assayed immediately, and aliquots of 1.5ml were
preserved for prostaglandin assays.
Indomethacin treatment Indomethacin (Sigma) was
included in some of the culture media at a
concentration of 1 pgml-1.
In vitro osteolysis by tumour cell lines
Thirteen cell lines were examined. Ten of the lines
(LICR/HN 1-10) were established by Easty et al.
(1981a, b) and the other 3 (LICR/HN 12, 13 and
15) by one of us (S.-W.T.) using the same
techniques. Validation of the tumour cell lines in
terms of their karyotypes, ultrastructure and growth
as xenografts is provided in the papers by Easty
and her colleagues.
Subconfluent cultures of carcinoma cells were
incubated with modified Bigger's medium
(supplemented with 5% heat-inactivated rabbit
serum and antibiotics) for 24h at 37°C in 5% CO2
in air (40ml per culture flask, 174cm3, Nunc). Cell
free supernatants were prepared by filtration
(0.45pm Millipore filter). After adjusting the pH to
the same value as control medium (- 7.4), the
conditioned media were added to cultures of 45Ca-
labelled calvaria. The pH of the culture medium
was measured again at the end of experiment.
Eight control fibroblastoid cell lines were also
established from primary explant cultures of
squamous carcinomas which had been overgrown
by fibroblastoid cells. They were examined in the
same way as the carcinoma cell lines.
Indomethacin was included in some of the culture
media at a concentration of 1 pgml- -.
Radioimmunoassay ofprostaglandins
Prostaglandins present in culture media were
extracted in ether, and purified by thin-layer
chromatography (Eastman & Dowsett, 1976). Total
recovery after these steps was 50%, calculated by
adding a radiolabelled prostaglandin tracer. The
purified prostaglandins were then quantitated by
standard radioimmunoassay using two antisera
raised separately against PGE2 and PGF2a from
Steranti laboratories and [3H]-labelled PGE2
(16OCimM-1) and PGF2a (l80CimM-1) from
Amersham International Ltd. Technical details are
given in Tsao (1982).
Histology
Fresh soft tissues were fixed after culture in formol
saline, embedded in paraffin wax, processed by
routine histological techniques and stained with H
and E. Incubated calvaria were fixed in formol
saline, decalcified in EDTA, embedded in
methacrylate resin and cut at 1-2pm.
Results
Observations withfresh tumour tissues
In vitro osteolysis by tumours co-cultured with
bone Osteolytic activity in 16 unselected squamous
carcinomas is summarized in Table I. Twelve of the
tumours examined showed bone resorption withBONE DESTRUCTION BY SQUAMOUS CARCINOMAS 699
Table I In vitro osteolysis by 16 freshly-excised
squamous carcinomas of the head and neck co-cultured
with radiolabelled mouse calvaria
Amount of
tumour per 45Ca release
Site of bone (mg Indomethacin (Test/control
primary tumour wet wt) (1Pgml-1) ratio)
Hypopharynx 28.2 - 2.49+0.23
28.2 + al.91 +0.13
Floor of mouth 15.0 - 2.06+0.23
15.6 + 1.51+0.33
Oropharynx - 2.01 +0.05
+ 1.17+0.11
Nasal septumd 15.6 - 1.94+0.09
15.8 + al.50+0.05
Oropharynx - 1.94+0.10
Tonguec - 1.81 +0.08
+ 1.30+0.10
Floor of mouth 12.7 - 1.80+0.14
Floor ofmouthd 18.8 - 1.69+0.22
18.5 + 1.48+0.15
Tongue 13.2 - 1.59+0.15
14.8 + 1.26+0.17
Hypopharynx 11.1 - 1.51+0.10
12.9 + al.11+0.04
Tongue 16.1 - 1.49+0.08
17.3 + 1.50+0.19
Hypopharynx - 1.30+0.13
+ a1.03+0.05
Larynxc 19.4 - 1.19+0.10
19.6 + 1.08+0.06
Hypopharynx 9.5 - 1.19+0.09
10.5 + 1.03+0.03
Nasal septumc 13.3 - 1.16+0.17
11.5 + 1.05+0.13
Tongue 14.5 - 1.09+0.03
16.0 + 1.03+0.02
ap<0.05 calculated according to Student's t-test.
bp<0.01 calculated according to Student's t-test.
Cnodal metastases.
dbone invasion demonstrated in the surgical specimen.
45calcium release test/control ratios . 1.3.
Differences in pH between test and control culture
media were small (usually <0.1). No consistent
association was established between in vitro
osteolysis and a tumour's site, size, degree of
differentiation or the presence of bone invasion
or lymph node metastases.
Indomethacin was added to 14 of the co-culture
experiments; the concentration used (1 ugml-1) has
been shown to suppress prostaglandin synthesis to
insignificant levels in this assay (<1 ngml-'see
Tsao (1982). The results are included in Table I.
Osteolysis was blocked to varying degrees by
indomethacin and, in 10 tumours (71%), the level
of inhibition was near to or greater than 50% of
the total osteolytic activity. Inhibition was
statistically significant in 6 tumours (P<0.05,
Student's t-test). This consistent but incomplete
blocking of tumour-associated bone resorption by
indomethacin suggests that both prostaglandins
and indomethacin-resistant (non-prostaglandin)
osteolysins are produced.
In order to show that indomethacin affected the
synthesis of new osteolytic factors rather than the
action of osteolytic factors already released into the
medium, the drug was also added to 3 tumour-
conditioned media after instead of during the
incubation period with tumour. Osteolysis was only
slightly affected, confirming that indomethacin acts
mainly by inhibiting prostaglandin formation.
In vitro osteolysis and prostaglandin release in
tumour-conditionedmedia Synchronousobservations
on in vitro osteolysis and prostaglandin
release were made with tumour-conditioned
media (3 days incubation) from a further
12 tumours. The results are shown in Table II.
Varying degrees of bone resorption were
detected. Prostaglandins, especially PGE2, were
demonstrated in the conditioned media but the
levels varied widely (42-120ngml-1, mean
+s.d. =32.9+36.7ngml-1) and bore no direct
relationship to the osteolysis observed. The amount
of PGE2 required to stimulate in vitro bone
resorption in this system is -5 to lOngml-l (Tsao,
1982) so the PGE2 detected in the tumour-
Table II In vitro osteolysis and prostaglandin release in
pre-conditioned media from 12 freshly-excised squamous
carcinomas of the head and neck
Prostaglandins
45Ca release: (ngml 1)
Site of test/control
primary tumour ratio PGE2 PGF2.
Larynx 2.80+0.10 42.6 5.0
Tongue' 2.61 +0.19 12.0 0.8
Larynx 2.58+0.10 93.6 3.5
Larynx 2.56+0.07 15.1 12.9
Tongue 2.55+0.14 12.6 10.1
Tongue' 2.53+0.36 19.3 2.1
Hypopharynx 2.40+0.16 13.0 3.2
Tongue 2.33+0.08 4.2 4.3
Hypopharynx 2.30+0.02 25.6 3.8
Maxillary
antrumb 2.25+0.06 120.0 3.2
Larynx 2.12+0.25 32.8 5.3
Tongueb 1.70+0.09 4.5 0.2
Mean +s.d.Mean +s.d.
32.9+36.7 4.5+3.6
(n=12) (n=12)
anodal metastases.
bbone invasion demonstrated in surgical specimen.700 S.-W. TSAO et al.
conditioned media would account for at least part
of the osteolytic activity demonstrated. PGF2a was
present in only small amounts and is unlikely to
stimulate bone resorption to any extent.
Histological structure was well-preserved in the
tumours after 3 days co-culture with calvaria. All
the fragments contained intact carcinoma. Foci of
necrosis, inflammation and fibrosis were also
present.
Observations with control tissues Two sets of
control tissues were examined: uninvolved tissues
from the head and neck removed from surgical
specimens at the same time as the tumours, and
normal skin from reduction mammaplasties.
Tissues from the head and neck Osteolytic activity
in 12 paired tumours and non-neoplastic tissues is
shown in Table III. Ten of the control tissues
resorbed bone in vitro. Activity was usually greater
in the corresponding tumour, but the differences
were small and reached statistical significance in
only one instance (P<0.01, Student's t-test).
Prostaglandins were measured in conditioned media
from 4 of the pairs. Similar levels of PGE2 were
found in tumour and control tissues in 3 of the 4
pairs, the fourth showing an excess of PGE2 in the
tumour. Levels of PGF2a followed no consistent
pattern in the material examined. Sections from the
cultured tissues showed no evidence of tumour but
a variable amount of focal necrosis and mixed
inflammatory infiltrates with mononuclear cells,
lymphocytes and sometimes polymorphs.
Normal skin In vitro bone resorption and
prostaglandin release were examined in 4 specimens
of breast skin. Osteolysis was either weak or absent
(45Calcium release: test/control ratios of 0.87+0.02,
1.10+0.04, 1.48+0.14, 1.47+0.10). The amounts
of prostaglandin detected were too low to stimulate
bone resorption (PGE2<2.9ngml-1 and
PGF2a<1.3ngml1-). The cultured breast skin was
histologically normal.
Observations with carcinoma cell lines
In vitro osteolysis Eleven carcinoma cell lines were
tested for bone resorbing activity using conditioned
culture media (24h incubation) obtained from
subconfluent monolayer cell cultures. The results
are shown in Table IV. Varying degrees of
osteolysis were detected. Cell lines LICR/HN 2, 4,
6, 7, 10, 12 and 13 were moderately active and
LICR/HN 1, 3, 5, and 9 were less active. The
variations in activity noted among individual cell
lines in repeated assays probably reflect variations
in culture conditions such as cell density and
Table III In vitro osteolysis and prostaglandin release by
paired neoplastic and non-neoplastic tissues
45Ca release Prostaglandins
test/control (ngml-1)
Tissue ratio PGE2 PGF2a
A) Bone resorption in co-culture experiments:
Tumour 2.06+0.23
(Floor ofmouth)
Control 1.89+0.12
Tumour 1.94+0.08
(Nasal septum)
Control 1.74+0.12
Tumour 1.8+0.13
(Floor ofmouth)b
Control 1.18+0.04
Tumour 1.58+0.13
(Tongue)
Control 1.44+0.08
Tumour 1.5+0.11
(Hypopharynx)
Control 1.48+0.16
Tumoura 1.19+0.02
(Larynx)
Control 1.0+0.04
Tumour 1.19+0.08
(Hypopharynx)
Control 1.28+0.08
Tumour 1.08+0.03
(Tongue)
Control 1.22+0.23
B) Bone resorption and prostaglandin release in
conditioned media:
Tumour 2.58+0.10 93.6 3.5
(Larynx)
Control 2.14+0.14 96.4 10.9
Tumour 2.55+0.07 15.1 12.9
(Larynx)
Control 2.45+0.21 14.0 2.4
Tumour 2.55+0.14 12.6 10.1
(Tongue)
Control 0.90+0.03 1.4 1.5
Tumour 2.40+0.16 13.0 3.2
(Hypopharynx)
Control 2.68+0.16 17.2 5.2
anodal metastases.
bp<0.01 by Student's t-test.
batches of serum used. The pH differences between
the test and control media were low (<0.1).
Indomethacin (1 4gml-) was added to cultures
of five of the active cell lines (LICR/HN 2, 4, 6, 7
and 12). Control medium contained the same
amount of indomethacin. The results are shown in
Table IV. In contrast to the findings with freshlyBONE DESTRUCTION BY SQUAMOUS CARCINOMAS 701
Table IV In vitro osteolysis by 11 tumour cell lines
derived from squamous carcinomas of the head and neck
-~~~~~~~~~~~~~~~~~~~~
Cell Passage de
lines number (x J
LICR/HN 6 20
(Tongue) 29
26
26
LICR/HN 4a 16
(Larynx)
24
24
LICR/HN 7 24
(Tongue)
21
LICR/HN 13
(Oropharynx)
LICR/HN 10a
(Larynx)
LICR/HN 2a
(Larynx)
LICR/HN 12
(Hypopharynx)
LICR/HN 1
(Tongue)
LICR/HN 5
(Tongue)
LICR/HN 9
(Tongue)
LICR/HN 3
(Tongue)
7
Cell Indo- 45Ca release
ensity methacin (testl
05ml-1)(1 jgml-1) control)
2.9 - 1.87+0.14
- 1.83+0.13
3.4 - 2.02+0.22
3.6 + 2.19+0.15
2.2 - 1.60+0.06
1.9 - 2.21 +0.10
2.3 + 2.18+0.10
- 1.75+0.07
- 1.50+0.06
+ 1.68+0.02
- 1.64+0.07
4 2.7
32
33
33
21
14
17
20
48
52
7
15
34
39
aBone invasion observed
excised tumours (cf. T<
were observed. The red
lines LICR/HN 2 a]
significant.
Radioimmunoassay c
carcinoma cell lines (L
prostaglandin concer
activities were determ
medium. The results a
concentrations of prost
(PGE2<3.5ngml-1, P4
not correlate with the
observed.
Table V Comparison of in vitro osteolysis and levels of
prostaglandins E2 and F2. in cell culture supernatants
from 5 squamous carcinoma cell lines
Prostaglandins
(ngml-1)
Passage 45Ca release
Cell line number (test/control) PGE2 PGF2,
LICR/HN 6
(Tongue) 29 1.83+0.13 0.7 0.21
LICR/HN 4
(Tongue) 16 1.60+0.06 3.3 0.2
LICR/HN 5
(Tongue) 52 1.32+0.02 0.7 0.22
LICR/HN 1
(Tongue) 20 1.31 +0.03 1.5 0.2
LICR/HN 3
(Tongue) 39 1.27+0.07 1.4 1.3
- 1.61+0.05
9.5 - 1.50+0.08 Radioimmunoassay of prostaglandins was
extended to the supernatant culture media collected
from other tumour cell lines obtained under the
11.5 1.55+0.09 same conditions as the bone resorption assay. The
9.4 + 1.30+0.04 mean concentrations of prostaglandins detected in
- 1.50+0.09 media from all 13 lines were generally low (PGE2:
+ 1.34+0.05 3.3 +2.7ngml1, PGF2a: 0.25+0.21ngml-') though
1.9 - 1.35+0.14 3 cell lines (LICR/HN 7, 10 and 13) released higher
1.9 - 1.52+0.13 amounts of PGE2 (6.5-8.8ngml-1); these values are
- 1.31 +0.03 just significant in stimulating bone resorption in
2.6 - 1.28+0.03 vitro (Tsao, 1982) and may account for a small
- 1.32+0.02 proportion of the osteolytic activities previously
- 1.21 +0.09 observed.
- 1.20+0.07 Histological changes were examined in paired test
0.89+0.04 and control calvaria from experiments with tumour
- 127+007 cell lines LICR/HN 1, 2, 4 and 6. All slides were -1.27 +0.07 coded beforehand, but differences between the two
in original surgical specimens. groups were readily apparent. Bone incubated in
control media felt firm when handled, and sections
subsequently showed smooth intact trabeculae with
only occasional multinucleate osteoclasts. Bones
able I), no consistent effects incubated with media from the carcinoma cell lines
uced osteolysis seen with cell felt soft and sections showed a loss of bone
nd 12 is not statistically substance with thin and irregularly outlined
trabeculae and increased numbers of osteoclasts on
or near the internal bone surface. The osteoclastic
)f prostaglandins In 5 response was most marked in calvaria exposed to
,ICR/HN 1, 3, 4, 5 and 6), media from tumour cell lines LICR/HN 4 and 6;
atrations and osteolytic these two lines showed high levels of in vitro
lined in the same culture osteolysis and produced predominantly non-
ire shown in Table V. The prostaglandin osteolysins (see Table IV).
taglandins detected were low
GF2a<1.3ngml-1) and did
levels of osteolytic activity
Observations with control (fibroblastoid) cell
cultures Fibroblastoid cell lines were examined for
in vitro osteolysis and release of prostaglandins.702 S.-W. TSAO et al.
The results are shown in Table VI. Osteolytic
activity was detected in 4/8 cultures. Differences in
pH between test and control media were
insignificant (pH<0.01). Prostaglandins were
determined in media from two osteolytically active
lines (FB 1 and 6) and two inactive lines (FB 2 and
4). The concentrations detected were low
(PGE2 <2.0ngml-'; PGF2a<0.7ngml-1) and were
too small to stimulate bone resorption in vitro.
Table VI In vitro osteolysis and prostaglandin release by
fibroblastoid cell lines
Prosta-
45Ca glandins
Fibro- Cell release (ngml-1)
blastoid Passage density (test
cells number (x JO ml-1) control) PGE2 PGF2a
FB1 2 2.2 1.61+0.04 ND ND
4 ND 2.0 0.2
FB5 5 1.60+0.23 ND ND
FB6 7 ND 1.5 0.23
8 1.58+0.14 ND ND
FB7 3 1.32+0.09 ND ND
F4 2 2.2 1.11+0.01 ND ND
3 ND 1.5 0.7
FB2 2 2.7 1.09+0.09 ND ND
3 ND 1.5 ND
FB 8 5 0.90+0.05 ND ND
FB 3 2 1.0 0.85+0.05 ND ND
ND=not done.
Discussion
Three main groups of findings have emerged from
this work. Freshly excised squamous carcinomas of
the head and neck resorb bone in vitro. Osteolytic
activity, mediated by local osteoclasts, is
consistently reduced (though not abolished) by
indomethacin. The tumours release E2
prostaglandins (PGE2): the levels are variable but
are sufficient to account for at least 50% of the
bone resorption observed in most instances. Cell
lines derived from squamous cancers are also
osteolytic in vitro but differ from fresh tumours in
two respects. Bone resorption by most of the cell
lines is largely unaffected by indomethacin and
production of PGE2 is low, suggesting that
prostaglandins are mainly implicated in osteolysis
by fresh tumours. No differences in activity were
observed between tumours treated pre-operatively
by irradiation and/or cytotoxic drugs and tumours
treated by primary surgery. Non-neoplastic tissues
show a variable capacity to resorb bone in vitro,
indicating that osteolysis is not a tumour-specific
activity.
Several human tumours produce prostaglandins
in vitro, notably carcinomas of the breast (Bennet et
al., 1975, 1976, 1977a; Powles et al., 1976; Dowsett
et al., 1976; Greaves et al., 1980) kidney (Atkins et
al., 1977) and large intestine (Bennett et al., 1977b).
Prostaglandins from human tumours resorb bone in
vitro, and extensive studies of prostaglandin-
mediated osteolysis have been made with
experimental tumours (Tashjian et al., 1972, 1982;
Voelkel et al., 1978; Tashjian, 1978). Activation of
local osteoclasts has been observed in the in vitro
model systems (Schelling et al., 1980). Investigators
have been unable to establish a linear relationship
between levels of prostaglandins released and the
mass of bone resorbed, and it has become apparent
that additional non-prostaglandin osteolytic factors
are also involved. Particular discussion continues in
relation to two topics-the cellular origin of the
osteolysins and their nature, especially with
respect to non-prostaglandin substances.
(1) The complementary use of fresh tissues and
cell lines provides a starting point for separating
tumour and host cells as potential sources of
osteolytic agents. In the experiments described here
with paired tumour and control tissues, most of the
fresh control tissues resorbed bone in vitro and
released prostaglandins at levels not significantly
less than the corresponding tumour. The absence of
tumour in control tissues was always confirmed
histologically, but they were invariably inflamed
and had usually been exposed to pre-operative
irradiation and/or chemotherapy; although such
tissues form acceptable controls for the tumours
from the same patients, they clearly cannot be
regarded as normal. By contrast, histologically
normal breast tissue with no necrosis or
inflammatory infiltrates showed negligible osteolysis
and prostaglandin release. Mononuclear
macrophages can synthesise prostaglandins and
resorb bone in vitro (Mynett et al., 1975; Humes et
al., 1977; Mundy et al., 1977; Kahn et al., 1978;
McArthur et al., 1980) and there is evidence that
bone resorption in rheumatoid arthritis and
peridontal inflammation may be partly due to local
production of prostaglandins (Robinson et al.,
1975; Harris, 1978). Some of the control
fibroblastoid cell lines resorbed bone in vitro but
PGE2 levels were always low. Taken together, these
findings suggest an association between the capacity
of non-neoplastic tissues to manifest prostaglandin-
mediated bone resorption in vitro and the presence
of inflammatory cells within them. This is a
difficult topic to pursue in intact tissues as the
inflammatory infiltrates would need to be
quantified and each of the cell constituents
accurately identified.
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(indomethacin-insensitive) osteolysins remains
obscure. Candidates include ectopic parathyroid
hormone, osteoclast activating factors and certain
other ill-defined products (Mundy et al., 1974a, b;
Josse et al., 1981; Nimberg et al., 1982). The non-
prostaglandin osteolysin associated with squamous
cancers of the head and neck is uncharacterized at
the present time.
No consistent relationship has emerged between
bone resorbing activity and prostaglandin release in
vitro, clinicopathological features of the tumours
(including the presence of bone invasion in the
surgical specimens) and post-operative survival of
the patients. A similar lack of correlation has been
reported in patients with breast cancer (Dady et al.,
1981) though prognostic significance for raised
prostaglandin levels has been claimed by other
workers (Fitzpatrick & Stringfellow, 1979).
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